Results 201 to 210 of about 19,833 (262)

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

Andrology, Volume 14, Issue 6, Page 1627-1635, September 2026.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin, Xuefeng Ding, Xin Dang, Qingyuan Zhan   +3 more
wiley   +1 more source

Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT Aim Patients with chronic kidney disease (CKD) have an increased cardiovascular risk. Since neutrophils and neutrophil‐borne proteins contribute to cardiovascular disease, we analyzed the neutrophil phenotype in patients with CKD who presented with a spectrum of cardiovascular comorbidities.
Sonja Vondenhoff, Alessandra Antwerpen, Carolina Victoria Cruz Junho, Philipp Martin, Sina Hourtz, Jinmi Zou, Berkan Kurt, Carolin Haas, Susanne Fleig, Corinna Schulte, Jane Lauxen, Martina Wessiepe, Ulrike Späte‐Schulze, Rafael Kramann, Jürgen Floege, Oliver Soehnlein, Joachim Jankowski, Claudia Goettsch, Yvonne Döring, Florian Kahles, Nikolaus Marx, Constance C. F. M. J. Baaten, Heidi Noels   +22 more
wiley   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock, Chantal Mathieu, Joshua Buron Feinberg, Priyanka Rao, Cathrine Scavenius, Alice Y. Y. Cheng   +5 more
wiley   +1 more source

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

, 2020
Rhee SY, Lee J, Nam H, Kyoung D, Kim DJ.
europepmc   +1 more source

Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7814-7824, September 2026.
ABSTRACT Aim This Finnish nationwide retrospective 'real‐world' study evaluated the effects of oral semaglutide on glycaemic control, body weight, lipid profile, and liver enzymes in adults living with type 2 diabetes (T2D) and naïve to any GLP‐1 receptor agonists in Finland.
Atte Vaden, Mari Lahelma, Lalli Nurmi, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero Saukkonen, Leo Niskanen   +7 more
wiley   +1 more source

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7950-7963, September 2026.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies

Expert Opinion on Drug Safety, 2018
Type 2 diabetes (T2D), a multifactorial and chronic disease, requires in an elevated percentage of patients the association of several antidiabetic drugs to achieve optimal glycemic control. Dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter inhibitors (SGLT2i) are new classes of oral antidiabetic drugs developed over the last ...
FRANCISCO J Tinahones, Maria Molina-Vega, Araceli Muñoz-Garach   +2 more
exaly   +3 more sources

Pharmacoeconomic analysis of DPP-4 inhibitors

Die Pharmazie, 2013
Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi, H, Ohta, T, Tachi, M, Toyoshima, T, Mizui, C, Goto, T, Tsuchiya   +6 more
openaire   +3 more sources

The Research Progress of DPP-4 Inhibitors

Mini-Reviews in Medicinal Chemistry, 2020
Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients.
Zhi-Gang, Sun, Zhi-Na, Li, Hai-Liang, Zhu   +2 more
openaire   +2 more sources